Global Vaccine Adjuvants Market Analysis & Forecast (2018-2023) - Expanding Government Recommendations for Immunizations Drives the Market - ResearchAndMarkets.com

DUBLIN--()--The "Vaccine Adjuvants Market - Segmented By Type, Mechanism of action (Active immunostimulants, Carriers, and Vehicle adjuvants), and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

Expanding government recommendations for immunizations, increasing technological innovations, unmet vaccine market needs for certain diseases, and increasing use of recombinant subunit and synthetic vaccines are the major factors contributing to the growth of the global vaccine adjuvants market which is expected to reach USD 1,036.40 million in 2023.

Key Highlights

  • Expanding Government Recommendations for Immunizations Drives the Vaccine Adjuvants Market
  • Side Effects of Adjuvants is Restricting the Growth of the Vaccine Adjuvants Market
  • Mineral Salt Based Adjuvants has the Largest Market Share
  • Vehicle Adjuvants have Registered a High CAGR
  • North America is Anticipated to Dominate the Vaccine Adjuvants Market

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Vaccine Adjuvants Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

6.1 Market Drivers

6.1.1 Expanding government recommendations for immunizations

6.1.2 Technological innovations

6.1.3 Unmet Vaccine market needs for certain diseases

6.1.4 Increasing use of recombinant subunit and synthetic vaccines

6.2 Market Restraints

6.2.1 Side effects of adjuvants

6.2.2 High toxicity adjuvants

6.2.3 High R&D developing a new adjuvant

7. Market Segmentation

7.1 By type

7.2 By Mechanism of action

7.3 By Geography

7.3.1 North America

7.3.2 Europe

7.3.3 AsiaPacific

7.3.4 Middle East & Africa

7.3.5 South America

8. Competitive Landscape

9. Company Profiles

9.1 Invivogen

9.2 Sigma Aldrich (Merck KGaA)

9.3 Seppic (Air Liquide Group)

9.4 Oz Biosciences

9.5 Novavax, Inc

9.6 Adjuvatis

9.7 Vaxliant

9.8 Adjuvance Technologies, Inc

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/fnvr8n/global_vaccine?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines